Browse > Article
http://dx.doi.org/10.4014/jmb.1412.12027

Production of Recombinant Human Papillomavirus Type 52 L1 Protein in Hansenula polymorpha Formed Virus-Like Particles  

Liu, Cunbao (Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College)
Yao, Yufeng (Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College)
Yang, Xu (Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College)
Bai, Hongmei (Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College)
Huang, Weiwei (Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College)
Xia, Ye (Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College)
Ma, Yanbing (Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College)
Publication Information
Journal of Microbiology and Biotechnology / v.25, no.6, 2015 , pp. 936-940 More about this Journal
Abstract
Human papillomavirus (HPV) type 52 is a high-risk HPV responsible for cervical cancer. HPV type 52 is common around the world and is the most common in some Asian regions. The available prophylactic HPV vaccines protect only from HPV types 16 and 18. Supplementing economical vaccines that target HPV type 52 may satisfactorily complement available prophylactic vaccines. A codon-adapted HPV 52 L1 gene was expressed in the methylotrophic yeast Hansenula polymorpha, which is used as an industrial platform for economical hepatitis B surface antigen particle production in China. We found that the recombinant proteins produced in this expression system could form virus-like particles (VLPs) with diameters of approximately 50 nm. This study suggests that the HPV 52 VLPs produced in this platform may satisfactorily complement available prophylactic vaccines in fighting against HPVs prevalent in Asia.
Keywords
Human papillomavirus type 52 L1; Hansenula polymorpha; virus-like particles;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM. 2007. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int. J. Cancer 121: 621-632.   DOI   ScienceOn
2 Liu C, Yang X, Yao Y, Huang W, Sun W, Ma Y. 2014. Diverse expression levels of two codon-optimized genes that encode human papillomavirus type 16 major protein L1 in Hansenula polymorpha. Biotechnol. Lett. 36: 937-945.   DOI   ScienceOn
3 Mbayeel HS, Gheit T, Dem A, McKay-Chopin S, ToureKane NC, Mboup S, et al. 2014. Human papillomavirus infection in women in four regions of Senegal. J. Med. Virol. 86: 248-256.   DOI   ScienceOn
4 Quek SC, Lim BK, Domingo E, Soon R, Park JS, Vu TN, et al. 2013. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical intraepithelial neoplasia across 5 countries in Asia. Int. J. Gynycol. Cancer 23: 148-156.   DOI   ScienceOn
5 Simonella LM, Lewis H, Smith M, Neal H, Bromhead C, Canfell K. 2013. Type-specific oncogenic human papillomavirus infection in high grade cervical disease in New Zealand. BMC Infect. Dis. 13: 114.   DOI
6 Takehara K, Toda T, Nishimura T, Sakane J, Kawakami Y, Mizunoe T, et al. 2011. Human papillomavirus types 52 and 58 are prevalent in uterine cervical squamous lesions from Japanese women. Patholog. Res. Int. 2011: 246936.
7 Zhao FH, Zhu FC, Chen W, Li J, Hu YM, Hong Y, et al., HPV-039 study group. 2014. Baseline prevalence and type distribution of human papillomavirus in healthy Chinese women aged 18-25 years enrolled in a clinical trial. Int. J. Cancer 135: 2604-2611.   DOI   ScienceOn
8 Zhao Q, Allen MJ, Wang Y, Wang B, Wang N, Shi L, Sitrin RD. 2012. Disassembly and reassembly improves morphology and thermal stability of human papillomavirus type 16 virus-like particles. Nanomedicine 8: 1182-1189.   DOI   ScienceOn
9 Lee EH, Um TH, Chi HS, Hong YJ, Cha YJ. 2012. Prevalence and distribution of human papillomavirus infection in Korean women as determined by restriction fragment mass polymorphism assay. J. Kor. Med. Sci. 27: 1091-1097.   DOI   ScienceOn
10 Hoang HT, Ishizaki A, Nguyen CH, Tran VT, Matsushita K, Saikawa K, et al. 2013. Infection with high-risk HPV types among female sex workers in northern Vietnam. J. Med. Virol. 85: 288-294.   DOI   ScienceOn
11 Lin H, Ma YY, Moh JS, Ou YC, Shen SY, ChangChien CC. 2006. High prevalence of genital papillomavirus type 52 and 58 in women attending gynecologic practitioners in south Taiwan. Gynecol. Oncol. 101: 40-45.   DOI   ScienceOn
12 Kim HJ, Kwag HL, Kim HJ. 2013. Codon optimization of the human papillomavirus type 58 L1 gene enhances the expression of soluble L1 protein in Saccharomyces cerevisiae. Biotechnol. Lett. 35: 413-421.   DOI   ScienceOn
13 Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. 1992. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. USA 89: 12180-12184.   DOI   ScienceOn
14 Li HM, Liang GJ, Yin YP, Wang QQ, Zheng ZJ, Zhou JJ, et al. 2012. Prevalence and genotype distribution of human papillomavirus infection among female sex workers in Guangxi, China: implications for interventions. J. Med. Virol. 84: 798-803.   DOI   ScienceOn
15 Garland SM, Smith JS. 2010. Human papillomavirus vaccines: current status and future prospects. Drugs 70: 1079-1098.   DOI   ScienceOn
16 Hanumantha Rao N, Baji Babu P, Rajendra L, Sriraman R, Pang YY, Schiller JT, Srinivasan VA 2011. Expression of codon optimized major capsid protein (L1) of human papillomavirus type 16 and 18 in Pichia pastoris; purification and characterization of the virus-like particles. Vaccine 29: 7326-7334.   DOI   ScienceOn
17 Chui SH, Szeto YT, Lam CW. 2012. Human papillomavirus infection in Macau women. Public Health 126: 600-604.   DOI   ScienceOn
18 Bian G, Cheng Y, Wang Z, Hu Y, Zhang X, Wu M, et al. 2009. Whole recombinant Hansenula polymorpha expressing hepatitis B virus surface antigen (yeast-HSsAg) induces potent HBsAg-specific Th1 and Th2 immune responses. Vaccine 28: 187-194.   DOI   ScienceOn
19 Chen Q, Xie LX, Qing ZR, Li LJ, Luo ZY, Lin M, et al. 2012. Epidemiologic characterization of human papillomavirus infection in rural Chaozhou, eastern Guangdong Province of China. PLoS One. 7: e32149.   DOI
20 Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S. 2010. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J. Infect. Dis. 202: 1789-1799.   DOI   ScienceOn
21 Deschuyteneer M, Elouahabi A, Plainchamp D, Plisnier M, Soete D, Corazza Y, et al. 2010. Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in CervarixTM, the AS04-adjuvanted HPV-16 and -18 cervical cancer vaccine. Hum. Vaccine 6: 407-419.   DOI
22 Diminsky D, Schirmbeck R, Reimann J, Barenholz Y. 1997. Comparison between hepatitis B surface antigen (HBsAg) particles derived from mammalian cells (CHO) and yeast cells (Hansenula polymorpha): composition, structure and immunogenicity. Vaccine 15: 637-647.   DOI   ScienceOn
23 Faber KN, Haima P, Harder W, Veenhuis M, AB G. 1994. Highly-efficient electrotransformation of the yeast Hansenula polymorpha. Curr. Genet. 25: 305-310.   DOI